 |
|
|
| |
12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE
INHIBITOR AND RBV ACHIEVED SVR24 IN
>90% OF TREATMENT-NÁVE HCV GT1
PATIENTS AND 47% OF PRIOR NONRESPONDERS
|
| |
| |
Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections
Atlanta, GA · March 3-6, 2013
Eric Lawitz1, Daniel E. Cohen2, Fred Poordad1, Kris V. Kowdley3, Gregory T. Everson4, Bradley Freilich5, Donald Jensen6, Tami Pilot-Matias2, Barry Bernstein2
1: University of Texas Health Science Center, San Antonio, TX, 2: AbbVie Inc., North Chicago, IL, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: University of Colorado Denver and University of Colorado Hospital, Aurora,CO, 5: Kansas City Gastroenterology & Hepatology, Kansas City, MO, 6: Center for Liver Diseases, University of Chicago Medical Center Chicago, Chicago, IL
|
| |
|
|
|
|
|
